Please enable JavaScript to continue using this application.

Compare $CLDX vs $PGEN | Chartloom

Compare

$CLDX vs $PGEN

Celldex Therapeutics Inc · Precigen Inc

CLDX

Celldex Therapeutics Inc

PGEN

Precigen Inc

Compare $CLDX vs $PGEN

Comparing Celldex Therapeutics Inc and Precigen Inc

CLDXCelldex Therapeutics Inc

PGENPrecigen Inc

CLDXCelldex Therapeutics Inc

Market cap

$2.35B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1,016.81x

Rev growth (TTM)

-97.3%

YTD performance

10.7%

52W performance

9.7%

FCF yield

-10.3%

PGENPrecigen Inc

Market cap

$2.78B

P/E (TTM)

—

Forward P/E (NTM)

13.49x

Forward P/S (NTM)

8.46x

Rev growth (TTM)

1875.0%

YTD performance

82.5%

52W performance

142.5%

FCF yield

-4.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CLDX

PGEN

Detailed metrics comparison

CLDX

Celldex Therapeutics Inc

PGEN

Precigen Inc

Market Cap

CLDX$2.35B

PGEN$2.78B

Enterprise Value

CLDX$2.30B

PGEN$2.86B

Price

CLDX$29.89

PGEN$7.81

P/E Ratio

CLDXN/A

PGENN/A

P/S Ratio

CLDX14,848.52x

PGEN32.48x

EV/Sales

CLDX14,548.18x

PGEN33.39x

EV/EBITDA

CLDX0.00x

PGEN0.00x

P/B Ratio

CLDX3.48x

PGEN70.17x

P/FCF Ratio

CLDXN/A

PGENN/A

EV/FCF

CLDX-9.49x

PGEN-24.84x

PEG Ratio

CLDXN/A

PGENN/A

Forward P/E (NTM)

CLDXN/A

PGEN13.49x

Forward P/S (NTM)

CLDX1,016.81x

PGEN8.46x

Revenue (TTM)

CLDX$158K

PGEN$86M

Revenue Growth (YoY)

CLDX-97.3%

PGEN1875.0%

Forward Rev Growth

CLDX637.2%

PGEN95.1%

Gross Margin (TTM)

CLDX17.6%

PGEN90.7%

Operating Margin (TTM)

CLDX0.0%

PGEN0.0%

EBITDA Margin (TTM)

CLDX-204070.9%

PGEN-41.3%

Net Margin (TTM)

CLDX-190220.9%

PGEN-392.8%

FCF Margin (TTM)

CLDX-153231.0%

PGEN-134.4%

Net Income (TTM)

CLDX$-301M

PGEN$-337M

FCF (TTM)

CLDX$-242M

PGEN$-115M

EPS (TTM)

CLDX-$3.86

PGEN-$0.81

ROE (TTM)

CLDX-5235.0%

PGEN-49832.0%

ROA (TTM)

CLDX-4761.0%

PGEN-9923.0%

ROIC (TTM)

CLDX-5235.0%

PGEN-12615.0%

Cash

CLDX$47M

PGEN$16M

Debt

CLDX$0

PGEN$94M

Net Cash/Debt

CLDX$47M

PGEN$-78M

Current Ratio (TTM)

CLDX11.82x

PGEN4.58x

Quick Ratio (TTM)

CLDX11.71x

PGEN3.76x

Debt/Equity (TTM)

CLDX0.00x

PGEN2.15x

Debt/Assets (TTM)

CLDX0.0%

PGEN0.0%

Interest Coverage (TTM)

CLDXN/A

PGENN/A

Net Debt/EBITDA (TTM)

CLDX0.00x

PGEN0.00x

Beta

CLDX0.99

PGEN0.99

52W Performance

CLDX9.7%

PGEN142.5%

YTD Performance

CLDX10.7%

PGEN82.5%

% from 52W High

CLDX-33.8%

PGEN-13.0%

% from 52W Low

CLDX35.2%

PGEN161.2%

Asset Turnover (TTM)

CLDX0.00x

PGEN0.54x

FCF Yield (TTM)

CLDX-10.3%

PGEN-4.1%

Earnings Yield (TTM)

CLDX-12.8%

PGEN-12.1%

Dividend Yield (TTM)

CLDXN/A

PGENN/A

Rule of 40

CLDX-153,328.3

PGEN1,740.6

EV/GP/RG

CLDX42.93

PGEN0.13

Ticker research

View CLDX research View PGEN research

Metric	CLDX Celldex Therapeutics Inc	PGEN Precigen Inc
Market & Valuation
Market Cap	$2.35B	$2.78B
Enterprise Value	$2.30B	$2.86B
Price	$29.89	$7.81
P/E Ratio	N/A	N/A
P/S Ratio	14,848.52x	32.48x
EV/Sales	14,548.18x	33.39x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.48x	70.17x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.49x	-24.84x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	13.49x
Forward P/S (NTM)	1,016.81x	8.46x
Revenue & Growth
Revenue (TTM)	$158K	$86M
Revenue Growth (YoY)	-97.3%	1875.0%
Forward Rev Growth	637.2%	95.1%
Profitability
Gross Margin (TTM)	17.6%	90.7%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-204070.9%	-41.3%
Net Margin (TTM)	-190220.9%	-392.8%
FCF Margin (TTM)	-153231.0%	-134.4%
Net Income (TTM)	$-301M	$-337M
FCF (TTM)	$-242M	$-115M
EPS (TTM)	-$3.86	-$0.81
ROE (TTM)	-5235.0%	-49832.0%
ROA (TTM)	-4761.0%	-9923.0%
ROIC (TTM)	-5235.0%	-12615.0%
Financial Health
Cash	$47M	$16M
Debt	$0	$94M
Net Cash/Debt	$47M	$-78M
Current Ratio (TTM)	11.82x	4.58x
Quick Ratio (TTM)	11.71x	3.76x
Debt/Equity (TTM)	0.00x	2.15x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	0.99
52W Performance	9.7%	142.5%
YTD Performance	10.7%	82.5%
% from 52W High	-33.8%	-13.0%
% from 52W Low	35.2%	161.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.54x
FCF Yield (TTM)	-10.3%	-4.1%
Earnings Yield (TTM)	-12.8%	-12.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-153,328.3	1,740.6
EV/GP/RG	42.93	0.13
Ticker research	View CLDX research	View PGEN research

Valuation

P/S Ratio

PGEN

32.48x

CLDX

14,848.52x

EV/FCF

PGEN

-24.84x

CLDX

-9.49x

Growth & revenue

Revenue Growth TTM

PGEN

1875.0%

CLDX

-97.3%

Forward Revenue Growth

CLDX

637.2%

PGEN

95.1%

Profitability & performance

Gross Margin

PGEN

90.7%

CLDX

17.6%

ROE

CLDX

-5235.0%

PGEN

-49832.0%

FCF Yield %

PGEN

-4.1%

CLDX

-10.3%

52-Week Performance

PGEN

142.5%

CLDX

9.7%

Detailed metrics comparison

CLDX

Celldex Therapeutics Inc

PGEN

Precigen Inc

Market Cap

CLDX$2.35B

PGEN$2.78B

Enterprise Value

CLDX$2.30B

PGEN$2.86B

Price

CLDX$29.89

PGEN$7.81

P/E Ratio

CLDXN/A

PGENN/A

P/S Ratio

CLDX14,848.52x

PGEN32.48x

EV/Sales

CLDX14,548.18x

PGEN33.39x

EV/EBITDA

CLDX0.00x

PGEN0.00x

P/B Ratio

CLDX3.48x

PGEN70.17x

P/FCF Ratio

CLDXN/A

PGENN/A

EV/FCF

CLDX-9.49x

PGEN-24.84x

PEG Ratio

CLDXN/A

PGENN/A

Forward P/E (NTM)

CLDXN/A

PGEN13.49x

Forward P/S (NTM)

CLDX1,016.81x

PGEN8.46x

Revenue (TTM)

CLDX$158K

PGEN$86M

Revenue Growth (YoY)

CLDX-97.3%

PGEN1875.0%

Forward Rev Growth

CLDX637.2%

PGEN95.1%

Gross Margin (TTM)

CLDX17.6%

PGEN90.7%

Operating Margin (TTM)

CLDX0.0%

PGEN0.0%

EBITDA Margin (TTM)

CLDX-204070.9%

PGEN-41.3%

Net Margin (TTM)

CLDX-190220.9%

PGEN-392.8%

FCF Margin (TTM)

CLDX-153231.0%

PGEN-134.4%

Net Income (TTM)

CLDX$-301M

PGEN$-337M

FCF (TTM)

CLDX$-242M

PGEN$-115M

EPS (TTM)

CLDX-$3.86

PGEN-$0.81

ROE (TTM)

CLDX-5235.0%

PGEN-49832.0%

ROA (TTM)

CLDX-4761.0%

PGEN-9923.0%

ROIC (TTM)

CLDX-5235.0%

PGEN-12615.0%

Cash

CLDX$47M

PGEN$16M

Debt

CLDX$0

PGEN$94M

Net Cash/Debt

CLDX$47M

PGEN$-78M

Current Ratio (TTM)

CLDX11.82x

PGEN4.58x

Quick Ratio (TTM)

CLDX11.71x

PGEN3.76x

Debt/Equity (TTM)

CLDX0.00x

PGEN2.15x

Debt/Assets (TTM)

CLDX0.0%

PGEN0.0%

Interest Coverage (TTM)

CLDXN/A

PGENN/A

Net Debt/EBITDA (TTM)

CLDX0.00x

PGEN0.00x

Beta

CLDX0.99

PGEN0.99

52W Performance

CLDX9.7%

PGEN142.5%

YTD Performance

CLDX10.7%

PGEN82.5%

% from 52W High

CLDX-33.8%

PGEN-13.0%

% from 52W Low

CLDX35.2%

PGEN161.2%

Asset Turnover (TTM)

CLDX0.00x

PGEN0.54x

FCF Yield (TTM)

CLDX-10.3%

PGEN-4.1%

Earnings Yield (TTM)

CLDX-12.8%

PGEN-12.1%

Dividend Yield (TTM)

CLDXN/A

PGENN/A

Rule of 40

CLDX-153,328.3

PGEN1,740.6

EV/GP/RG

CLDX42.93

PGEN0.13

Ticker research

View CLDX research View PGEN research

Metric	CLDX Celldex Therapeutics Inc	PGEN Precigen Inc
Market & Valuation
Market Cap	$2.35B	$2.78B
Enterprise Value	$2.30B	$2.86B
Price	$29.89	$7.81
P/E Ratio	N/A	N/A
P/S Ratio	14,848.52x	32.48x
EV/Sales	14,548.18x	33.39x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.48x	70.17x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.49x	-24.84x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	13.49x
Forward P/S (NTM)	1,016.81x	8.46x
Revenue & Growth
Revenue (TTM)	$158K	$86M
Revenue Growth (YoY)	-97.3%	1875.0%
Forward Rev Growth	637.2%	95.1%
Profitability
Gross Margin (TTM)	17.6%	90.7%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-204070.9%	-41.3%
Net Margin (TTM)	-190220.9%	-392.8%
FCF Margin (TTM)	-153231.0%	-134.4%
Net Income (TTM)	$-301M	$-337M
FCF (TTM)	$-242M	$-115M
EPS (TTM)	-$3.86	-$0.81
ROE (TTM)	-5235.0%	-49832.0%
ROA (TTM)	-4761.0%	-9923.0%
ROIC (TTM)	-5235.0%	-12615.0%
Financial Health
Cash	$47M	$16M
Debt	$0	$94M
Net Cash/Debt	$47M	$-78M
Current Ratio (TTM)	11.82x	4.58x
Quick Ratio (TTM)	11.71x	3.76x
Debt/Equity (TTM)	0.00x	2.15x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	0.99
52W Performance	9.7%	142.5%
YTD Performance	10.7%	82.5%
% from 52W High	-33.8%	-13.0%
% from 52W Low	35.2%	161.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.54x
FCF Yield (TTM)	-10.3%	-4.1%
Earnings Yield (TTM)	-12.8%	-12.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-153,328.3	1,740.6
EV/GP/RG	42.93	0.13
Ticker research	View CLDX research	View PGEN research